MiRXES

Executive Summary

MiRXES is a Singapore-based RNA diagnostics company leveraging microRNA (miRNA) technology to develop minimally invasive blood tests for early cancer detection and tissue-based profiling for treatment selection. Founded in 2014, the company has raised $120 million and is publicly listed. Its flagship products include GASTROClear for gastric cancer and LUNGClear for lung cancer, along with comprehensive gene panels (APEX and COMPASS) and infectious disease RT-PCR kits. MiRXES aims to address high mortality rates through earlier intervention and has established commercial presence in Asia, with ongoing efforts to expand into global markets. The company's platform is validated through multiple clinical studies, and it continues to invest in R&D to broaden its test portfolio. Commercially, MiRXES is generating revenue from test sales and partnerships, though profitability and scale remain key focus areas. Upcoming catalysts include potential regulatory approvals in the US and China, interim clinical data readouts for lung and gastric cancer tests, and strategic collaborations with global diagnostics firms. The company's unique miRNA-based approach and proven test performance position it well in the fast-growing liquid biopsy market, but execution risks and competitive pressures persist. Overall, MiRXES represents a high-potential player in early cancer diagnostics with multiple near-term milestones that could drive value.

Upcoming Catalysts (preview)

• Q4 2026FDA submission for GASTROClear or LUNGClear approval in the US55% success
• Q1 2027Pivotal trial interim data for LUNGClear65% success
• Q3 2026Strategic partnership with a global diagnostics or pharmaceutical company for distribution in new markets45% success